Entinostat (MS-275)

For research use only. Not for use in humans.

目录号:S1053 别名: SNDX-275 中文名称:恩替诺特

Entinostat (MS-275) Chemical Structure

CAS No. 209783-80-2

Entinostat (MS-275, SNDX-275)强烈抑制HDAC1HDAC3,无细胞试验中IC50分别为0.51 μM和1.7 μM,抑制作用强于HDACs 4, 6, 8,和10。Entinostat可诱导自噬和凋亡。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 746.45 现货
RMB 564.33 现货
RMB 1233.32 现货
RMB 2234.07 现货
RMB 6301.79 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Entinostat (MS-275)发表文献300篇:

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Entinostat (MS-275, SNDX-275)强烈抑制HDAC1HDAC3,无细胞试验中IC50分别为0.51 μM和1.7 μM,抑制作用强于HDACs 4, 6, 8,和10。Entinostat可诱导自噬和凋亡。Phase 3。
靶点
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
体外研究

MS-275通过作用于2′-氨基而抑制HDACs。MS-275作用于 K562细胞,诱导 p21WAF1/CIP1和凝溶胶蛋白的累积。MS-275作用于A2780细胞,可以降低S期细胞,提高G1期细胞。 MS-275通过抑制HAD而抑制人类肿瘤细胞系,包括 A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St和 HCT-15细胞增殖, IC50 为41.5 nM到4.71 μM。[1]MS-275抑制HDACs,作用于HDAC1和 HDAC3时IC50 分别为0.51 μM和1.7 μM。而对其他的HDACs没有抑制效果,如HDAC4, 6, 8和10。[2]MS-275有效抑制人类白血病和淋巴癌细胞,包括U937, HL-60, K562, 和Jurkat。MS-275可以诱导U937细胞p21CIP1/WAF1 调节的生长和变异Marker (CD11b)的表达。MS-275降低cyclin D1和抗凋亡蛋白Mcl-1与XIAP的表达。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 M1q5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzIV|FpUUN3ME2wMlA3OSEQvF2= NEPnSoRUSU6JRWK=
ALL-PO M3HYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzZTWM2OD1yLkC2N|U2KM7:TR?= NYfScGN7W0GQR1XS
697 NX;WW41IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3mxV2lEPTB;MD6wPVk4PiEQvF2= M4P2bHNCVkeHUh?=
NCI-H748 MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfPPVA1UUN3ME2wMlExOzN2IN88US=> MnLxV2FPT0WU
NKM-1 M1L0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMUC5NVIh|ryP NH6wRYxUSU6JRWK=
ES1 NUXKXYZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvHcXVQUUN3ME2wMlEyOjV3IN88US=> Mkf2V2FPT0WU
NCI-H1963 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XaeGlEPTB;MD6xNVU4QSEQvF2= NXjJdm5wW0GQR1XS
NCI-H1417 M1;USGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zzNmlEPTB;MD6xNlk4PCEQvF2= NUDqfFZXW0GQR1XS
NEC8 Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7JfnIzUUN3ME2wMlE{PTJ5IN88US=> NVnpSFVvW0GQR1XS
CRO-AP2 NH33O2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMU[4PFkh|ryP NHO1bHZUSU6JRWK=
A3-KAW NFnXUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjGTm1qUUN3ME2wMlE4PjJ5IN88US=> NVqxbIxOW0GQR1XS
SF539 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfOZXV{UUN3ME2wMlE6PTl|IN88US=> NWjuXoNDW0GQR1XS
NOS-1 NYGyUldMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT5fJZzUUN3ME2wMlE6PjF7IN88US=> MnTLV2FPT0WU
NTERA-S-cl-D1 NYT0Xo0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vkXGlEPTB;MD6yNFEyOyEQvF2= M4rYb3NCVkeHUh?=
COR-L88 M3TXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMkK5OVkh|ryP NVfBdmlxW0GQR1XS
EM-2 NIjIZWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLlRWhmUUN3ME2wMlI1ODd7IN88US=> NV;Kd5ZKW0GQR1XS
KARPAS-45 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDZOpF{UUN3ME2wMlI4QDN|IN88US=> MlTVV2FPT0WU
DSH1 NXPS[3M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwMki3NFgh|ryP NHnmXlFUSU6JRWK=
HT-144 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWW2OIlYUUN3ME2wMlMxOjV4IN88US=> M3XvfHNCVkeHUh?=
ATN-1 NX;EcVNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwM{C1O|Yh|ryP MYHTRW5ITVJ?
HEL NF\NZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2T1W2lEPTB;MD6zNVM1QCEQvF2= M33XOXNCVkeHUh?=
NB12 NYLuRoNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrNTIl4UUN3ME2wMlMyPzV4IN88US=> M1vpOXNCVkeHUh?=
LU-139 M{jISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInCSWRKSzVyPUCuN|M2OSEQvF2= MWTTRW5ITVJ?
J-RT3-T3-5 MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwM{O3NVYh|ryP M4DNeHNCVkeHUh?=
MOLT-13 NWL0TXM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjURWpKSzVyPUCuN|M5OSEQvF2= MX7TRW5ITVJ?
SR NFX1OVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwM{SyOlEh|ryP NVHtW3VHW0GQR1XS
CMK NUDWepVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfwTWM2OD1yLkO1O|I4KM7:TR?= NIjaRY9USU6JRWK=
ES8 NX;E[2JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HpcWlEPTB;MD6zOlAzOiEQvF2= MlLtV2FPT0WU
LB647-SCLC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwM{[3N{DPxE1? NVTVWm5nW0GQR1XS
TE-8 Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwM{[5N|Uh|ryP Mn65V2FPT0WU
BV-173 NX36NJM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3WepVKSzVyPUCuN|cyOjFizszN NHf6c41USU6JRWK=
DEL MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4joSWlEPTB;MD6zO|Q5PyEQvF2= NEnQRVhUSU6JRWK=
ARH-77 Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\xSoFKSzVyPUCuN|gyQTNizszN NVjjeXpVW0GQR1XS
NCCIT MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL5N4pZUUN3ME2wMlM5PjR7IN88US=> NHK4XHdUSU6JRWK=
RPMI-8402 NE\3U2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTlbXVnUUN3ME2wMlM5PzBzIN88US=> NHHGcYRUSU6JRWK=
MONO-MAC-6 NH;NSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLKTWM2OD1yLkO4O|c3KM7:TR?= NXz1O2s4W0GQR1XS
SK-MM-2 NWDWOod2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInYOG1KSzVyPUCuN|k5PjhizszN M2S5UXNCVkeHUh?=
CHP-126 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwNECyN|Eh|ryP MXPTRW5ITVJ?
A101D NFj0[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjNb2VbUUN3ME2wMlQxOyEQvF2= M2qzfXNCVkeHUh?=
SCH MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXr5N4ZiUUN3ME2wMlQxOzR{IN88US=> M4rQdnNCVkeHUh?=
NMC-G1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7CVo1qUUN3ME2wMlQxOzZ5IN88US=> M4\JSXNCVkeHUh?=
NCI-H209 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDkOZJKSzVyPUCuOFA3OTNizszN M4S3OHNCVkeHUh?=
MOLT-16 MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwNEGwNVch|ryP M2HaOnNCVkeHUh?=
RPMI-6666 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwNEGxNkDPxE1? NYPUPFl1W0GQR1XS
OPM-2 MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwNEG1NVMh|ryP MoLxV2FPT0WU
MRK-nu-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2q1VGlEPTB;MD60N|E2OyEQvF2= NYnvd2htW0GQR1XS
BC-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3keXA2UUN3ME2wMlQ{PDB|IN88US=> Ml;CV2FPT0WU
MHH-NB-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7qTWM2OD1yLkSzOFU{KM7:TR?= MlXIV2FPT0WU
Ramos-2G6-4C10 NWD4NVJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjNOGROUUN3ME2wMlQ{QDl5IN88US=> Mo[zV2FPT0WU
LS-513 M4fr[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fPcWlEPTB;MD60OFUxOSEQvF2= MULTRW5ITVJ?
K5 M1:0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwNEewNlUh|ryP MWHTRW5ITVJ?
HOP-62 M4n1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGK3UpNKSzVyPUCuOFg{PThizszN MXXTRW5ITVJ?
NCI-H187 NHH6d5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr2bmJvUUN3ME2wMlQ6OjJ5IN88US=> NW\RVpFMW0GQR1XS
BE-13 M3jZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwNEm2OlEh|ryP M33GXHNCVkeHUh?=
HC-1 NVXHUFByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDIXmV[UUN3ME2wMlUxPDd|IN88US=> M3;PVXNCVkeHUh?=
ACN M3q5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwNUGwNlgh|ryP MXXTRW5ITVJ?
HCC1599 M17kbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwNUG1O{DPxE1? M17xSXNCVkeHUh?=
MV-4-11 NFzyZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\sN2lEPTB;MD61N|A1OSEQvF2= NEnq[IhUSU6JRWK=
LC-2-ad NFniR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPJTWM2OD1yLkWzOlY{KM7:TR?= NEO0b2ZUSU6JRWK=
HL-60 MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zsVWlEPTB;MD61OFI3OSEQvF2= NYHL[HRyW0GQR1XS
NB17 NEDRPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwNUSzPEDPxE1? NXvrUGJJW0GQR1XS
TE-1 NVnVVJpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwNUWzNFYh|ryP NHnZRppUSU6JRWK=
NCI-H524 Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXTZnZOUUN3ME2wMlU2PDBzIN88US=> M13YWXNCVkeHUh?=
MZ7-mel M4T5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrqN5lKSzVyPUCuOVYyODVizszN MlTtV2FPT0WU
L-363 MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXKwW5I4UUN3ME2wMlU3PjV5IN88US=> NI\zZXVUSU6JRWK=
BL-41 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwNU[4PFkh|ryP M3Kz[3NCVkeHUh?=
LU-134-A NEf4UnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTaPGd2UUN3ME2wMlU4ODd|IN88US=> MnXaV2FPT0WU
SIG-M5 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[weWlEPTB;MD61O|g1QCEQvF2= MYjTRW5ITVJ?
ONS-76 NXzBOI1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIC3cGxKSzVyPUCuOVgzPDJizszN MXzTRW5ITVJ?
KARPAS-299 NX\iZWc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPiTWM2OD1yLkW4OVA1KM7:TR?= Mn\yV2FPT0WU
DU-4475 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwNUi3NFMh|ryP NH\yTINUSU6JRWK=
NB69 NFOyTZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfGSZJsUUN3ME2wMlU6QDJ3IN88US=> NGjOOYxUSU6JRWK=
MHH-PREB-1 NFqwXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XUWWlEPTB;MD62NFcyQSEQvF2= MWjTRW5ITVJ?
LU-165 NVH4cFUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XPZWlEPTB;MD62NVgyOiEQvF2= NGfSfYdUSU6JRWK=
LOUCY MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLGTWM2OD1yLk[zN|Y1KM7:TR?= NUmxSnY1W0GQR1XS
NCI-H526 M3fER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkm3TWM2OD1yLk[zOVQyKM7:TR?= MVjTRW5ITVJ?
KE-37 NWHQb28xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i1TGlEPTB;MD62OFI4PiEQvF2= MlHjV2FPT0WU
NALM-6 M2PtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwNkS4OkDPxE1? NWDEepFPW0GQR1XS
CW-2 M3HhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvnV3NVUUN3ME2wMlY2Pzl2IN88US=> Mn;oV2FPT0WU
SU-DHL-1 NX2yUpFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTjeHFvUUN3ME2wMlY2QTR5IN88US=> MljyV2FPT0WU
NB13 Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwNk[4NVch|ryP MX;TRW5ITVJ?
QIMR-WIL MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHmdo96UUN3ME2wMlY5OzR|IN88US=> MoK0V2FPT0WU
ECC12 M4XuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XR[2lEPTB;MD63NFA5PiEQvF2= M33Md3NCVkeHUh?=
KALS-1 MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnafZExUUN3ME2wMlcxPDl{IN88US=> MmTjV2FPT0WU
COR-L279 Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\1VXhKSzVyPUCuO|A6QTZizszN M1f4bnNCVkeHUh?=
NB14 MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELtZ4ZKSzVyPUCuO|I3OTdizszN MnnkV2FPT0WU
CCRF-CEM NYHteG5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr5O2dmUUN3ME2wMlc1PjZzIN88US=> M{K3OHNCVkeHUh?=
SW954 M{PxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LFXGlEPTB;MD63OVk6QSEQvF2= M{nVPXNCVkeHUh?=
IST-SL1 Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwN{ezOFgh|ryP NF;HcWJUSU6JRWK=
LAMA-84 NFTSe|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwN{e1Olch|ryP MmDLV2FPT0WU
Daudi MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjkbmFKSzVyPUCuO|c3QDFizszN Mn;pV2FPT0WU
BC-3 NV70coRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXUTWM2OD1yLke4N|A5KM7:TR?= MYrTRW5ITVJ?
HCC2998 NWrmOHlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwN{izOkDPxE1? M4nhc3NCVkeHUh?=
NCI-H69 Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DuO2lEPTB;MD64NFE1PyEQvF2= NYfMfVFbW0GQR1XS
CPC-N M13TRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rYcmlEPTB;MD64NFUzPCEQvF2= M4\WVHNCVkeHUh?=
NOMO-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojPTWM2OD1yLkixNFg1KM7:TR?= MnjBV2FPT0WU
CESS NF\1T5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzv[HRKSzVyPUCuPFEyQTdizszN MojQV2FPT0WU
LC4-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjDSZFYUUN3ME2wMlg1ODB5IN88US=> M2jWO3NCVkeHUh?=
BL-70 M1PaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjOS3NKSzVyPUCuPFU4ODJizszN M4[xd3NCVkeHUh?=
ES4 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LocmlEPTB;MD64OVg3QCEQvF2= MYXTRW5ITVJ?
HCE-T MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfQdll3UUN3ME2wMlg4OTdzIN88US=> MVnTRW5ITVJ?
JAR NXmweXptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojDTWM2OD1yLki3PFI4KM7:TR?= NVPIWZpzW0GQR1XS
ST486 M{TQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;YSmxKUUN3ME2wMlg4QTF5IN88US=> Mn7NV2FPT0WU
KS-1 M3\aUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwOEiwPVYh|ryP MUjTRW5ITVJ?
GDM-1 MkPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3XTWM2OD1yLki4Olg4KM7:TR?= NFHpUppUSU6JRWK=
EHEB MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXmOVI5UUN3ME2wMlkzPTh3IN88US=> MoXyV2FPT0WU
LB2518-MEL M123[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCzSFllUUN3ME2wMlk{Ojh2IN88US=> MkWxV2FPT0WU
GOTO MmTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjtUIJ{UUN3ME2wMlk2ODd4IN88US=> M3q1ZXNCVkeHUh?=
LXF-289 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTDWIxKSzVyPUCuPVU6ODFizszN NGrGZ5lUSU6JRWK=
ES6 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\ZTWM2OD1yLkm2OFM4KM7:TR?= MYnTRW5ITVJ?
OS-RC-2 M{fTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXxPXo6UUN3ME2wMlk3QDNizszN MXrTRW5ITVJ?
DMS-153 MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwOUe0Olkh|ryP M2KyXHNCVkeHUh?=
SK-PN-DW NFiyUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETYbZdKSzVyPUCuPVc5OzFizszN M3HqUHNCVkeHUh?=
HH M{Lh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL6TWM2OD1yLkm4PVU6KM7:TR?= NYjrT5AzW0GQR1XS
SH-4 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzHTWM2OD1zLkCyOFEh|ryP M3jHO3NCVkeHUh?=
MOLT-4 MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj0ZXJKSzVyPUGuNFM1PTRizszN NYDiSJFuW0GQR1XS
TGW NHPl[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XS[mlEPTB;MT6wO|Y4PSEQvF2= NITrXmZUSU6JRWK=
L-540 NH\TfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHnRYFKSzVyPUGuNVA3ODRizszN NW\zNpdlW0GQR1XS
PF-382 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTybIJPUUN3ME2xMlEyPTF|IN88US=> MkjJV2FPT0WU
LC-1F Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTrUnhPUUN3ME2xMlEzODB5IN88US=> NGHU[|VUSU6JRWK=
OVCAR-4 NY\DTWR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHOb3BSUUN3ME2xMlE{OTZ3IN88US=> M3P4SnNCVkeHUh?=
A4-Fuk M3zzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nITmlEPTB;MT6xOVM3PCEQvF2= NVjK[|FnW0GQR1XS
HCC2218 NWrBeGtrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXNTWM2OD1zLkG2OlQyKM7:TR?= NG\wfZVUSU6JRWK=
HAL-01 NVjZSHZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrqUGdzUUN3ME2xMlE3QTR|IN88US=> M2rScHNCVkeHUh?=
IST-MEL1 MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWi2doZ1UUN3ME2xMlE4PjV7IN88US=> MnHtV2FPT0WU
NCI-H719 MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XkcGlEPTB;MT6xO|g6QCEQvF2= M4HJWXNCVkeHUh?=
EVSA-T NWXnfWVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fZdmlEPTB;MT6xPFEyPCEQvF2= NGnwZ5lUSU6JRWK=
SK-NEP-1 NHn0PZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTFwMkCyOlYh|ryP NYPjRpNsW0GQR1XS
OCUB-M NXn5WYFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;0bmlEPTB;MT6yNVQ5QSEQvF2= NULGdGd7W0GQR1XS
MEG-01 NU[zWZhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTFwMkKxNVgh|ryP Mnn4V2FPT0WU
no-10 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jh[mlEPTB;MT6yN|EyOiEQvF2= MnGwV2FPT0WU
MHH-CALL-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXPTWM2OD1zLkK0O|IyKM7:TR?= NY\ES5hSW0GQR1XS
SK-N-DZ MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrOXmVHUUN3ME2xMlI1Pzd4IN88US=> NV73XoJ7W0GQR1XS
SCLC-21H MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnYNJBKSzVyPUGuNlY1PzhizszN MVrTRW5ITVJ?
CTV-1 Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITGS4RKSzVyPUGuNlc1OjVizszN NFLJN2hUSU6JRWK=
NB1 M4m3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfk[JFKSzVyPUGuNlc4OzJizszN MU\TRW5ITVJ?
NCI-H64 MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPrRW1KSzVyPUGuNlg1PjJizszN MoLlV2FPT0WU
MDA-MB-134-VI M{TvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC5UW9GUUN3ME2xMlI5PTd5IN88US=> NILNeWJUSU6JRWK=
LB2241-RCC NIDido5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFwMki2OlMh|ryP MYTTRW5ITVJ?
8-MG-BA MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILlTHNKSzVyPUGuNlg5PjZizszN NUTuO2szW0GQR1XS
LP-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\JOmlEPTB;MT6yPVk1PyEQvF2= MX7TRW5ITVJ?
LS-411N NFTrV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3ITWwxUUN3ME2xMlMxQTl6IN88US=> M2fDeXNCVkeHUh?=
CAL-148 NWfae3ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jGeWlEPTB;MT6zNlU1OiEQvF2= NHvXcVhUSU6JRWK=
NCI-H2171 NHHtd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFwM{S1NFIh|ryP NUnySldLW0GQR1XS
JiyoyeP-2003 NIX4XlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXjcWZJUUN3ME2xMlM2OzlizszN NF23bINUSU6JRWK=
NCI-H2107 NVvYeoJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:wT5dKSzVyPUGuN|U5QDNizszN MWfTRW5ITVJ?
BB30-HNC NYfyOmw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPKTWM2OD1zLkO4PVc5KM7:TR?= MWfTRW5ITVJ?
K-562 M3;0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWH4RY9YUUN3ME2xMlM6OjF7IN88US=> NXG3Um5kW0GQR1XS
PSN1 M4nB[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\WW2lEPTB;MT60NlI5PyEQvF2= MWHTRW5ITVJ?
HCC2157 MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37Re2lEPTB;MT60NlY6OSEQvF2= NFLiXIFUSU6JRWK=
SBC-1 NGjkcohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFwNEK3OFEh|ryP NFy3R29USU6JRWK=
MC116 MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnVXGtKSzVyPUGuOFM3OTVizszN NXH4SGFlW0GQR1XS
KARPAS-422 M{D4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYWy[o8zUUN3ME2xMlQ2OzV6IN88US=> MXfTRW5ITVJ?
LB996-RCC M3XXemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjUTWM2OD1zLkS3NVA{KM7:TR?= MmG4V2FPT0WU
MSTO-211H NFWzTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7oTWM2OD1zLkS3PVg4KM7:TR?= Mn\hV2FPT0WU
BT-474 NX3jN5gyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\XTmlEPTB;MT61NVc3PCEQvF2= M323UHNCVkeHUh?=
A388 NHLZUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjCb2RKSzVyPUGuOVE6PDVizszN MULTRW5ITVJ?
SJSA-1 NXqwVpF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHnNohKSzVyPUGuOVIzPiEQvF2= M4TxbHNCVkeHUh?=
COLO-829 M17X[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW3O3NFUUN3ME2xMlU{PTZ2IN88US=> M1XYUHNCVkeHUh?=
KM-H2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml34TWM2OD1zLkW2Olch|ryP MX;TRW5ITVJ?
GR-ST NVy3[2Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rteGlEPTB;MT61OlgzKM7:TR?= M4P5S3NCVkeHUh?=
RPMI-8866 NILa[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjHTWM2OD1zLk[wNVQ1KM7:TR?= NVLqbWtmW0GQR1XS
KG-1 M1voPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDGTWM2OD1zLk[xPVAyKM7:TR?= NHPncW5USU6JRWK=
NCI-H82 NY\IdoZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFwNkO0NFYh|ryP M2\vfXNCVkeHUh?=
LB1047-RCC M1fHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fhdmlEPTB;MT62N|Q2QSEQvF2= NGDDemVUSU6JRWK=
KM12 NFTlVYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom5TWM2OD1zLk[0O{DPxE1? MkT6V2FPT0WU
NB5 M1fBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTFwNkW2O|ch|ryP MYDTRW5ITVJ?
HDLM-2 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4eyWWlEPTB;MT62PFI5OSEQvF2= NH\iSmhUSU6JRWK=
KU812 NWPifGg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[1PGw{UUN3ME2xMlY6PjB3IN88US=> M{KwVnNCVkeHUh?=
DB Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkj5TWM2OD1zLkewN|U{KM7:TR?= NHXQZoNUSU6JRWK=
HD-MY-Z Ml3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTFwN{WyN|Qh|ryP NUPvSpZJW0GQR1XS
KURAMOCHI Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknsTWM2OD1zLke3NlA4KM7:TR?= NXfpRmZTW0GQR1XS
ETK-1 NV7KVWw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknpTWM2OD1zLke4PFc6KM7:TR?= NWDuOoMzW0GQR1XS
SK-UT-1 M3\3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHiS3RKSzVyPUGuO|k{QDhizszN MonxV2FPT0WU
HUTU-80 NF;ucWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrsPI9KSzVyPUGuO|k2ODhizszN MYDTRW5ITVJ?
ES7 NHvNenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rMWmlEPTB;MT64NFMxOiEQvF2= MnX5V2FPT0WU
SW872 NEnmZ|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL2emJKSzVyPUGuPFE{QTVizszN NHXXVYdUSU6JRWK=
TK10 NIO4S4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\PXWlEPTB;MT64N|ExQCEQvF2= MXjTRW5ITVJ?
LB831-BLC NFS0NGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG3cZpJUUN3ME2xMlg{PTZ|IN88US=> NUTwb3lkW0GQR1XS
TE-9 MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L2[mlEPTB;MT64OFQzOiEQvF2= M{fXVHNCVkeHUh?=
MLMA MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvKfVNKSzVyPUGuPFgzOzRizszN MlflV2FPT0WU
D-542MG MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYP4foNJUUN3ME2xMlg6Ozd|IN88US=> M{\YdHNCVkeHUh?=
EW-16 MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3FTWM2OD1zLkmyO|Ih|ryP MkfxV2FPT0WU
LOXIMVI NHPQNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP0TWM2OD1zLkmzNlgh|ryP MVjTRW5ITVJ?
GB-1 NV3nWFEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHm[ZZKSzVyPUGuPVM5PjZizszN MkPqV2FPT0WU
IST-SL2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfiUm9sUUN3ME2yMlAxOjZ{IN88US=> MXrTRW5ITVJ?
LAN-6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjRS4VjUUN3ME2yMlAyQTZ4IN88US=> M1viRnNCVkeHUh?=
NCI-H510A NFTidoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITHZXhKSzVyPUKuNFQ2ODJizszN MkLvV2FPT0WU
NCI-H1092 NUTmV3FHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnDR4JIUUN3ME2yMlA2OTJ2IN88US=> MWrTRW5ITVJ?
HT MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr3bYJSUUN3ME2yMlExPDV2IN88US=> MV;TRW5ITVJ?
RL95-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXBNnQxUUN3ME2yMlEyPDh{IN88US=> M4L4O3NCVkeHUh?=
NCI-H1355 M37vfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDMTWM2OD1{LkGxO|kzKM7:TR?= MljCV2FPT0WU
NCI-H720 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDITWM2OD1{LkG2PFc{KM7:TR?= M16zbHNCVkeHUh?=
NCI-H1522 NFywWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TBNGlEPTB;Mj6yNVczOyEQvF2= NEnpW4dUSU6JRWK=
LB373-MEL-D M1LWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjlVIl[UUN3ME2yMlI3QTB{IN88US=> M3S3RnNCVkeHUh?=
DG-75 NWDGNWFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvKTWM2OD1{LkK3NVQ5KM7:TR?= MorBV2FPT0WU
ML-2 NU\rRW8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\icZo{UUN3ME2yMlMzQDV3IN88US=> NHXCfINUSU6JRWK=
SF126 NIDNdY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTuZ4FKSzVyPUKuN|MxQTRizszN MU\TRW5ITVJ?
MPP-89 M1PJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrpVGE4UUN3ME2yMlM{OTR3IN88US=> MkG4V2FPT0WU
NCI-H345 NXzSWZczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HueGlEPTB;Mj6zN|I4PyEQvF2= MV3TRW5ITVJ?
LS-123 NXjkUHYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzhZ|hKSzVyPUKuN|Q6OzZizszN M3LOVXNCVkeHUh?=
NB10 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLn[YtuUUN3ME2yMlQyODl{IN88US=> MnTIV2FPT0WU
CGTH-W-1 NFnINFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fTZ2lEPTB;Mj60NlI3PyEQvF2= MW\TRW5ITVJ?
CP66-MEL NH;IO|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLqflZKSzVyPUKuOFc4PyEQvF2= MoTUV2FPT0WU
L-428 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;jOGlEPTB;Mj60PFUzOSEQvF2= M{TENXNCVkeHUh?=
DMS-79 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXTN2tOUUN3ME2yMlU1OTB|IN88US=> MVzTRW5ITVJ?
NCI-H1882 M3;pfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LTPWlEPTB;Mj62O|U3OiEQvF2= M2C3d3NCVkeHUh?=
KGN NIHmRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJwN{[4O|Yh|ryP MW\TRW5ITVJ?
EW-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[yO3lKSzVyPUKuO|cxQDNizszN MoO5V2FPT0WU
U-266 NGjhXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHaU5Z7UUN3ME2yMlg1QDJ|IN88US=> Ml\pV2FPT0WU
COLO-320-HSR NYrrfm1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHk[ZpKSzVyPUKuPFU3PDFizszN NGLwb5dUSU6JRWK=
KMOE-2 NVPEfHpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJwOEe3NVEh|ryP NFfxPGlUSU6JRWK=
BB49-HNC NEfEXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTJwOUK0PEDPxE1? NV36eWJGW0GQR1XS
GI-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJwOUK5OVch|ryP NXfr[GVWW0GQR1XS
NCI-H1304 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjhdIVRUUN3ME2zMlAxPTFzIN88US=> MUHTRW5ITVJ?
NCI-H2227 M2fab2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\WTWM2OD1|LkCyNFc6KM7:TR?= NXPDR2tiW0GQR1XS
U-87-MG MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTNwMEO1NVMh|ryP MVnTRW5ITVJ?
NCI-H747 M1;PcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DzXmlEPTB;Mz6wOVIxPiEQvF2= Mmq4V2FPT0WU
CTB-1 NVLxSYV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTNwMEWzO|Yh|ryP MkmzV2FPT0WU
RPMI-8226 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfSUJRKSzVyPUOuNVQ{PzhizszN MXPTRW5ITVJ?
NCI-H2141 M3Pob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTNwMU[1OlYh|ryP NEfnPVVUSU6JRWK=
IST-MES1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PYdGlEPTB;Mz6xPFI4QSEQvF2= MU\TRW5ITVJ?
TE-5 MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Pqc2lEPTB;Mz6yNVM1OiEQvF2= NVvTVYF3W0GQR1XS
UACC-257 NUPlZ2JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTNwNEO2OVkh|ryP NHfuNoJUSU6JRWK=
SK-N-FI NHz3cYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS4TWM2OD1|LkS1NlI4KM7:TR?= Mlr3V2FPT0WU
MFH-ino NIf3dmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P2Z2lEPTB;Mz60OlU5QSEQvF2= MmCxV2FPT0WU
SF268 NWTFZ|BVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PFemlEPTB;Mz60PFE4PCEQvF2= MVTTRW5ITVJ?
TE-12 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HCRWlEPTB;Mz61NVY6QSEQvF2= MkHkV2FPT0WU
NB6 NWTQSlZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlm4TWM2OD1|LkW1OVY{KM7:TR?= NYrjXFloW0GQR1XS
DJM-1 NX;y[JNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXy1b49yUUN3ME2zMlU6QDl7IN88US=> M171XHNCVkeHUh?=
MZ1-PC M{ezcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fNTmlEPTB;Mz62NVYzPCEQvF2= NVzFZW01W0GQR1XS
OCI-AML2 MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G2[WlEPTB;Mz62NlY4OSEQvF2= M4rl[nNCVkeHUh?=
NCI-H1155 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTNwN{C5OFch|ryP MXHTRW5ITVJ?
RKO NXy1VpZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXRTo9KSzVyPUOuO|cyQDlizszN NVXGUHdSW0GQR1XS
ECC4 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml71TWM2OD1|Lkm3NVk2KM7:TR?= MknvV2FPT0WU
BB65-RCC MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jwWWlEPTB;Mz65O|U1PyEQvF2= NHLVNXlUSU6JRWK=
EB-3 M1e3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTNwOUm2N|Mh|ryP MlX1V2FPT0WU
SHP-77 NFjKU2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTRwMEC1NlQh|ryP MWnTRW5ITVJ?
NCI-H2196 M3X4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTRwMEW2NlUh|ryP MkHYV2FPT0WU
GI-ME-N NIX3ZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\JTWM2OD12LkC2N|k6KM7:TR?= M2\VZXNCVkeHUh?=
MN-60 NVzQfIZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTRwMUC4O{DPxE1? MWDTRW5ITVJ?
NCI-H1694 M4m2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\6WGlEPTB;ND6xN|QxPSEQvF2= MX3TRW5ITVJ?
LU-65 NUPXTo9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTxdYk4UUN3ME20MlE2OzN{IN88US=> NIDLOJdUSU6JRWK=
NCI-H1436 NI[1ZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnMXFlKSzVyPUSuNVg{OzNizszN NHPIR3BUSU6JRWK=
KINGS-1 MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T0ZWlEPTB;ND6zNVQ{OiEQvF2= MYjTRW5ITVJ?
GT3TKB NHvWTYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTRwM{OyOlgh|ryP M3zNb3NCVkeHUh?=
Becker NFjwPYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z3[GlEPTB;ND6zO|MyOiEQvF2= NVzJZVh7W0GQR1XS
HCC1187 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nrfWlEPTB;ND64PVY2PyEQvF2= NGfQXmlUSU6JRWK=
D-502MG NIXDO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonaTWM2OD13LkCwOFE3KM7:TR?= NGroSoZUSU6JRWK=
VA-ES-BJ MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTVwMUO3O|gh|ryP MoiwV2FPT0WU
NB7 NGfON4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrPeG9KSzVyPUWuNVQyOTJizszN MlTRV2FPT0WU
SW962 Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfZN|l1UUN3ME21MlM5QDF2IN88US=> M331S3NCVkeHUh?=
no-11 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLQZ2NKSzVyPUWuO|Y{PDNizszN NW\6O2JsW0GQR1XS
KNS-81-FD NVn3NIxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTVwOUC2PVQh|ryP M4q4fnNCVkeHUh?=
COLO-684 NEjwdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHftRXZKSzVyPUWuPVk1QTRizszN MojGV2FPT0WU
D-263MG M{LSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\EWII4UUN3ME22MlA5QDl3IN88US=> MWLTRW5ITVJ?
EW-24 MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;heVFKSzVyPU[uNlg2OSEQvF2= NWfFNoxjW0GQR1XS
TE-10 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;qfGlEPTB;Nj60NlYzOyEQvF2= MnHhV2FPT0WU
EKVX NIHnW|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlm5TWM2OD14LkS2N|IyKM7:TR?= NX;GfZlmW0GQR1XS
NCI-H1648 NES5d4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nZVGlEPTB;Nj62O|U2PyEQvF2= M13lXHNCVkeHUh?=
LB771-HNC MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTZwOUKzNFEh|ryP MULTRW5ITVJ?
SK-MEL-1 MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHYdoVwUUN3ME24MlE{OTZ4IN88US=> MWnTRW5ITVJ?
COLO-668 M1S5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1G3SmlEPTB;OD6yO|c5PiEQvF2= MXXTRW5ITVJ?
EW-12 M3XPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\wWmlEPTB;OD60NFgxOyEQvF2= MXzTRW5ITVJ?
A253 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\Y[ow5UUN3ME24Mlg1PjZzIN88US=> Mm\KV2FPT0WU
NCI-H2126 M1;4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljGTWM2OD16Lki5N|E6KM7:TR?= M4K1SHNCVkeHUh?=
Calu-6 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv4TXd4UUN3ME24Mlk6ODR{IN88US=> MVLTRW5ITVJ?
NCI-H23 MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTlwMUe3OFYh|ryP NFj3VmlUSU6JRWK=
WSU-NHL NVjE[IFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nLSmlEPTB;OT63O|Q4QCEQvF2= MXnTRW5ITVJ?
MMAC-SF NEnUU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTlwOUe5NFQh|ryP NXXTWI5qW0GQR1XS
SK-LMS-1 M3;tW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfxOY0{UUN3ME2xNE4zQDN2IN88US=> MkL4V2FPT0WU
GCIY NXy1OmFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTFyLkW5NlQh|ryP NIG2OoRUSU6JRWK=
TE-15 M4HHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTFzLk[wNFQh|ryP MWLTRW5ITVJ?
EoL-1-cell M1TaeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPrVYxKSzVyPUGxMlc3QDJizszN M3nzNHNCVkeHUh?=
NCI-H2081 NHO3TGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XWbGlEPTB;MUGuO|c5PiEQvF2= MYnTRW5ITVJ?
EW-3 M37tSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF{LkK0OlMh|ryP MVfTRW5ITVJ?
CAS-1 M3PNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS2O2hKSzVyPUGyMlM3OzFizszN NF36dldUSU6JRWK=
C2BBe1 NXTmUXBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fUeWlEPTB;MUKuOlE{OSEQvF2= NYnQe4ptW0GQR1XS
D-247MG M3HlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\yTWM2OD1zMj63PVUzKM7:TR?= M4rs[3NCVkeHUh?=
NCI-SNU-5 NFXBfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTF{LkiwNVMh|ryP MWjTRW5ITVJ?
LS-1034 Ml;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjuUopKSzVyPUG0MlM6PzVizszN MX\TRW5ITVJ?
EW-18 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nSSWlEPTB;MUSuOFQ5KM7:TR?= NX\zO|l6W0GQR1XS
Raji NFrIOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfaTWM2OD1zND61NFQ6KM7:TR?= NITyU3NUSU6JRWK=
D-283MED NY\MOYI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTF2Lk[yO|Eh|ryP MnrMV2FPT0WU
MZ2-MEL NX3vNpNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P2NmlEPTB;MUSuPVY6PiEQvF2= NEXQfWNUSU6JRWK=
NCI-SNU-16 M3nLRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LibmlEPTB;MUWuOFY{OyEQvF2= M1rvbnNCVkeHUh?=
P30-OHK Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETRWYlKSzVyPUG3Mlc5OzFizszN NVL6W4FkW0GQR1XS
RXF393 M{XzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LtT2lEPTB;MUmuNFE5PiEQvF2= NHXrfnNUSU6JRWK=
NCI-H1395 M3HlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XZe2lEPTB;MkCuOlcxOyEQvF2= MV;TRW5ITVJ?
U-698-M NEDRPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\BTWM2OD1{MD63NFc2KM7:TR?= M1rPPXNCVkeHUh?=
NCI-SNU-1 NETzOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDkcFNKSzVyPUKwMlczOjNizszN MXLTRW5ITVJ?
SW684 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv3PG1KSzVyPUKxMlE4OTZizszN M{LVPXNCVkeHUh?=
NCI-H716 NVexcYtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX1bIRRUUN3ME2yNU4{OTV2IN88US=> M2fINnNCVkeHUh?=
JVM-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm4TWM2OD1{MT60NVM{KM7:TR?= Mn\VV2FPT0WU
NCI-H1581 NWf4Omd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXWTWM2OD1{Mj60NVQ5KM7:TR?= NIPxRnFUSU6JRWK=
CA46 M4DKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTNzLk[5N|Yh|ryP M4Po[XNCVkeHUh?=
SNB75 M{XZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEi1SIZKSzVyPUOzMlY2ODNizszN MXrTRW5ITVJ?
KNS-42 NEfrO4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmO4TWM2OD1|NT65OlI1KM7:TR?= MVHTRW5ITVJ?
TUR M3nnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPISZVKSzVyPUO2MlA2OjFizszN NGXXRZpUSU6JRWK=
REH MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXMTlB3UUN3ME2zO{45OjFzIN88US=> NHnGSG9USU6JRWK=
EW-22 NGfPS2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvXfFRKSzVyPUSyMlI5QDVizszN MmfXV2FPT0WU
NCI-H446 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3QTWM2OD12Mj63PFU{KM7:TR?= M3[zNnNCVkeHUh?=
ES3 M3X0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7zRlVKSzVyPUSzMlE{OzlizszN MoSxV2FPT0WU
EW-11 NEfNfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTR2LkiyNVgh|ryP MXnTRW5ITVJ?
RH-1 NVnCfG9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq5RZZ2UUN3ME20O{42QDF{IN88US=> NGPMcYZUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; 

PubMed: 24203492     


HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. 

Cleaved PARP; 

PubMed: 19148581     


Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control.

Caspase 8 ; 

PubMed: 19148581     


Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression.

DR4 / DR5; 

PubMed: 19148581     


Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h.

TopoIIα / TopoIIβ; 

PubMed: 21254166     


Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.

24203492 19148581 21254166
Immunofluorescence
phalloidin / snail; 

PubMed: 29855565     


(C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed.

DR4 / DR5; 

PubMed: 19148581     


Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls.

H3K4Me3 / H3K9Me3; 

PubMed: 22468166     


Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.

29855565 19148581 22468166
Growth inhibition assay
Cell proliferation; 

PubMed: 24203492     


(A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. *, P < 0.05, **; P ≤ 0.01; ***, P ≤ 0.001

Cell viability; 

PubMed: 28969017     


PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.

24203492 28969017
ELISA
GCP-2 / MCP-2 / MIF ; 

PubMed: 24241152     


MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).

24241152
体内研究 MS-275按49 mg/kg剂量作用于除了HCT-15的人类移植瘤都显示出强抗癌活性。[1]MS-275促进恶性实体瘤和恶性血液病的治疗可能性,及生理和畸变基因表达的调节。[4]MS-275和IL-2联用,作用于肾细胞癌显示出强抗癌活性,因为降低调节性T细胞和增强脾细胞的表达。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[6]
- 合并

标准HDAC实验:

用HDAC buffer按1:6稀释鼠肝内的酶。重组人类HDACs按1:4稀释在HDAC buffer中。用于标准HDAC实验,60 μl HDAC buffer和10 μl 稀释的酶溶液在30oC混合。在HDAC buffer中加入30 μl基底液开始HDAC反应,随后在30oC下温育30分钟。加入100 μl胰蛋白酶溶液终止反应,胰蛋白酶溶液由溶于50 mM Tris-HCl(pH 为8.0)的10 mg/ml 胰蛋白酶, 100 mM NaCl,及 2 μM TSA组成。30oC下温育20分钟, 通过测定460纳米(λex = 390 nm)处的荧光监测AMC的释放。使用释放的AMC校准荧光强度 。用于标准时间过程实验,在初始100 μl HDAC 反应中加入20 pmol 基底物。2-50 pmol 基底物的酶法分析产物获得荧光AMC,通过测量这种荧光AMC来测定 Km值和 Vmax值。使用Hanes 图分析实验数据。记录的AMC信号是针对没有酶而有buffer和基底物的空白区。
细胞实验:[2]
- 合并
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St和HCT-15细胞
  • Concentrations: 10 μM 左右
  • Incubation Time: 3天
  • Method: 5×103个肿瘤细胞接种到96孔板上,加入梯度浓度MS-275培养三天。细胞用0.1 mg/mL中性红在CO2反应器中染色1小时,测定中性红与50 μL乙醇和150 μL 0.1 M Na2HPO4溶解后的OD540,测定IC50值。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 侧腹皮下注射A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1和Calu-3细胞的裸鼠
  • Dosages: 12.3, 24.5和49 mg/kg
  • Administration: 每天口服处理一次,每周进行5天,持续4周。
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+ddH2O
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 376.41
化学式

C21H20N4O3

CAS号 209783-80-2
储存条件 粉状
溶于溶剂
别名 SNDX-275

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03829930 Recruiting Drug: Entinostat|Drug: Enzalutamide Prostate Adenocarcinoma George Washington University May 1 2019 Phase 1
NCT03765229 Recruiting Drug: Entinostat|Drug: Pembrolizumab Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 22 2019 Phase 2
NCT03473639 Recruiting Drug: Entinostat|Drug: Capecitabine Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals January 29 2019 Phase 1
NCT03361800 Active not recruiting Drug: Entinostat Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI) November 28 2018 Early Phase 1
NCT03192111 Completed Drug: Entinostat Renal Impairment|Healthy Volunteer Syndax Pharmaceuticals July 27 2017 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • 回答:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Entinostat (MS-275) | Entinostat (MS-275)供应商 | 采购Entinostat (MS-275) | Entinostat (MS-275)价格 | Entinostat (MS-275)生产 | 订购Entinostat (MS-275) | Entinostat (MS-275)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID